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Serine/threonine phosphorylation of insulin receptor substrate-1 (IRS-1) regulates the function
and subsequent insulin signaling of this protein. Human IRS-1 has 1242 amino acid residues,
including 182 serines and 60 threonines. The size, complexity, and relatively low abundance of
this protein in biological samples make it difficult to map and quantify phosphorylation sites
by conventional means. A mass spectrometry peak area based quantification approach has
been developed and applied to assess the relative abundance of IRS-1 phosphorylation in the
absence or presence of stimuli. In this method, the peak area for a phosphopeptide of interest
is normalized against the average of peak areas for six selected representative IRS-1 peptides
that serve as endogenous internal standards. Relative quantification of each phosphopeptide
is then obtained by comparing the normalized peak area ratios for untreated and treated
samples. Two non-IRS-1 peptides were added to each digest for use as HPLC retention time
markers and additional standards as well as references to the relative quantity of IRS-1 in
different samples. This approach does not require isotopic or chemical labeling and can be
applied to various cell lines and tissues. Using this method, we assessed the relative changes
in the quantities of two tryptic phosphopeptides isolated from human IRS-1 expressed in L6
cells incubated in the absence or presence of insulin or tumor necrosis factor-. Substantial
increases of phosphorylation were observed for Thr446 upon stimulation. In contrast, no
obvious change in the level of phosphorylation was observed for Ser1078. This mass spectrom-
etry based strategy provides a powerful means to quantify changes in the relative phosphor-
ylation of peptides in response to various stimuli in a complex, low-abundance
protein. (J Am Soc Mass Spectrom 2006, 17, 562–567) © 2006 American Society for Mass
SpectrometryInsulin receptor substrate-1 (IRS-1), a member of theIRS family proteins [1], plays a central role in insulinsignaling. Tyrosine phosphorylation of IRS-1 by the
insulin receptor is necessary for intracellular transduc-
tion of insulin signaling; however, serine/threonine
phosphorylation also is involved in regulation of IRS-1
function [2]. Human IRS-1 has 1242 amino acid resi-
dues, including 182 serines and 60 threonines and is
present at low abundance, even in cell cultures. As
such, mapping and quantification of phosphorylation
sites in IRS-1 by conventional means is an extremely
difficult task. Approximately 40 serine/threonine phos-
phorylation sites have been identified from in vivo or in
Published online February 28, 2006
Address reprint requests to Dr. L. J. Mandarino, Department of Kinesiology,
Arizona State University, P.O. Box 874501, Tempe, AZ 85287-4501, USA.
E-mail: Lawrence.Mandarino@asu.edu
* Also affiliated with the Department of Kinesiology, Arizona State Univer-
sity, Tempe, Arizona.
© 2006 American Society for Mass Spectrometry. Published by Elsevie
1044-0305/06/$32.00 
doi:10.1016/j.jasms.2005.12.010vitro experiments, including 10 sites recently reported
by our group [2–11], although the biological functions
and relative quantification of most of these sites have
not yet been elucidated.
IRS-1 has been found to be phosphorylated at mul-
tiple serine and threonine sites in the basal state [9].
After stimulation with insulin or tumor necrosis factor-
(TNF), the overall level of phosphorylation increases, as
indicated by an upward shift in the migration of IRS-1 in
polyacrylamide gels [2, 12]. Because serine/threonine
phosphorylation of IRS-1 is believed to play an important
role in insulin resistance and type-2 diabetes mellitus [1,
13], relative quantification of IRS-1 phosphorylation under
various conditions is important to provide insight into the
molecular mechanism of insulin resistance. Site-specific
quantification of IRS-1 phosphorylation has been carried
out mainly by immunoblot analysis with specific antibod-
ies against the phosphorylated site. However, only several
such antibodies are commercially available, and genera-
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suming. Mass spectrometry provides a more efficient and
potentially more global way to identify and quantify
phosphorylated residues in IRS-1.
The power of matrix-assisted laser desorption ion-
ization time-of-flight mass spectrometry (MALDI-TOF/
MS) and high-performance liquid chromatography
electrospray ionization tandem mass spectrometry
(HPLC-ESI-MS/MS) as valuable tools to characterize
post-translational modifications is widely recognized
[14 –18]. However, quantification of protein phosphor-
ylation by mass spectrometry is still an analytical chal-
lenge [19, 20]. There are a variety of approaches that
have been employed for MS based quantification of
protein phosphorylation, including the use of stable
isotope labeled synthetic peptide analog internal stan-
dards [21, 22], metabolic labeling [23–26], derivatization
[27–29], and evaluation of MS peak intensities of pep-
tide(s) derived from proteins added before digestion
[19] or from the protein of interest [20, 30]. Of particular
note is the recent report by Steen and coworkers [20] in
which normalization of phosphopeptides was made
relative to “numerous” tryptic peptides from the target
protein; peptides were selected for normalization based
on a low relative deviation of signal intensity from the
mean when evaluated in multiple experiments. Al-
though the results obtained by that group were excel-
lent in terms of reproducibility, a relatively large num-
ber of samples is required to generate the requisite
dataset for curve fitting.
The use of peptides derived from the protein of interest
for normalization to assess the levels of phosphorylation
at specific sites offers clear advantages over othermethods
by accounting for differences in protein quantities among
samples and by providing an accurate reflection of diges-
tion efficiency. However, a key factor in this approach is
the selection of peptides suitable for normalization. In the
present report, we describe a straightforward strategy in
which we utilized reproducibly-detected “representative”
tryptic peptides that are distributed throughout the IRS-1
sequence for normalization to obtain relative quantities of
specific phosphopeptides. In each sample, we also in-
cluded two exogenous peptides to serve as additional
standards and HPLC retention time markers. Using this
approach, we assessed the effect of insulin or TNF
treatment of L6 cells on the relative phosphorylation at
two sites in human IRS-1. The results show that insulin or
TNF can increase the relative degree of phosphorylation
at Thr446 in IRS-1.
Methods
Materials
The following suppliers were used: PGEX-4T-3, Amer-
sham (Piscataway, NJ); XL1-Blue, Stratagene (La Jolla, CA);
glutathione-Sepharose beads, Amersham; sequencing-
grade trypsin, Promega (Madison,WI); OMIX C18 tips (10
l), Varian (Lake Forest, CA); anti HA.11, Covance (Berke-ley, CA). L6 myoblasts cells were a gift from Dr. Amira
Klip. The cDNA encoding full-length wild-type human
IRS-1 was a gift from Dr. C. Ronald Kahn (Harvard
University, MA).
Adenoviruses
Adenoviruses encoding green fluorescence protein (GFP,
as an adenovirus control) and hIRS-1 were produced
by using the AdEasy system (Quantum Biotechnologies,
Montreal, Canada). The cDNA encoding HA-tagged
hIRS-1 (pBEX-hIRS-1, prepared as previously described
[10]) was cloned into the pAdTrack-CMV transfer vector
using EcoR V and Xba I restriction sites. The hIRS-1-HA
encoding sequence was then transferred into the pAdEasy
viral DNA plasmid by homologous recombination in the
BJ5183 Escherichia coli strain. The recombinant adenoviral
construct was transfected in HEK293 cells to produce viral
particles. Adenoviruses were purified by CsCl gradient
centrifugation. The infection efficiency was estimated for
GFP expression using an Olympus CK40 (Melville, NY)
fluorescence microscope.
Cell Culture, Transfection, Immunoprecipitation,
and Western Blot Analysis
L6 cells were grown in MEM medium (Gibco, Invitro-
gen, Carlsbad, CA), supplemented with 10% fetal bo-
vine serum and 1% penicillin/streptomycin. For adeno-
virus experiments, cells were transduced with GFP
(control) or hIRS-1 adenovirus (Ad-hIRS-1). After 36 h
post-transfection/post-transduction, cells were serum-
starved for 2 to 4 h, treated with or without 100 nM
insulin 15 min or 10 nM TNF 30 min, washed three
times with ice-cold phosphate-buffered saline (PBS),
and lysed in 300 to 400 l of lysis buffer (50 mMHEPES,
pH 7.6, 150 mM NaCl, 1% Triton X-100, 10 mM NaF, 20
mM sodium pyrophosphate, 20 mM -glycerol phos-
phate, 1 mM sodium orthovanadate, 10 g/ml leupep-
tin, 10 g/ml aprotinin, 1 m microcystin-LR, and 1
mM phenylmethylsulfonyl fluoride). Cell lysates were
centrifuged (10,000  g, 4 °C, 10 min), and the clarified
supernatants were used for immunoprecipitation. For
immunoprecipitation, cell lysates were incubated with
specific antibodies for 2 to 4 h on ice and then with
protein G-agarose beads for 2 to 4 h at 4 °C with gentle
rotation. Immunoprecipitates were washed extensively
with ice-cold PTA buffer (PBS, pH 7.4, 0.5% Tween 20,
0.05% SDS, 0.1% BSA, 0.02% sodium azide). Proteins
bound to beads were eluted by heating at 95 °C for 4
min in SDS sample loading buffer. Eluted proteins were
separated by 10% SDS-PAGE and were stained with
Coomassie blue.
In-Gel Digestion
The bands containing full-length IRS-1 were excised,
washed twice with 400 l of 40 mM NH4HCO3,
564 YI ET AL. J Am Soc Mass Spectrom 2006, 17, 562–567destained with 200 l of 50% ACN in 40 mM
NH4HCO3, and dehydrated with 100% ACN for 10 min.
ACN was removed, the gel pieces were dried in a
vacuum centrifuge at 60 °C for 8 min, and digested in
situ with 400 ng trypsin (Promega) in 40 l of 40 mM
NH4HCO3 at 50 °C for 1 h; the reactions were termi-
nated by addition of 20 l 1% TFA. After incubation at
37 °C for 10 min and centrifugation for 1 min, each
supernatant was transferred to a clean tube. The extrac-
tion procedure was repeated after addition of 30 l of
0.1% TFA and the two extracts were combined. The
resulting peptide mixtures were purified on OMIX C18
tips after sample loading in 0.1% TFA and elution with
50% ACN/0.1% TFA (vol/vol). The samples were con-
centrated to 1 l by vacuum centrifugation and 14 l
of AngI/AngII (0.22 M each) in 0.1% TFA was added.
Mass Spectrometry
MALDI-TOF mass spectra were acquired on an Applied
Biosystems Voyager-DE STR (Foster City, CA) in reflec-
tron mode using dihydroxybenzoic acid as the matrix.
HPLC-ESI-MS/MS was performed on a Thermo Finni-
gan LCQ (San Jose, CA) which has been adapted for
microspray ionization. On-line HPLC separation of the
IRS-1 digests was accomplished with a Michrom BioRe-
sources Paradigm MS4 micro HPLC: column, PicoFrit
(New Objective, Woburn, MA; 75 m i.d.) packed to 10
cm with C18 adsorbent (Vydac, Hesperia, CA;
218MSB5, 5 m, 300 Å); mobile phase, linear gradient of
2 to 65% acetonitrile (ACN) in 0.5% acetic acid/0.005%
trifluoroacetic acid (TFA) for 30 min, a hold of 10 min at
65% ACN, and then a step to 80% ACN, hold 15 min;
flow rate, 0.4 l/min. Each digest was analyzed by
MALDI-TOF/MS with database analysis by Mascot
(Matrix Science, London, U.K.) to verify protein identity
before HPLC-ESI-MS/MS. Our protocol for “top-4”
data-dependent tandem MS analysis included acquisi-
tion of a full scan spectrum followed by collision-
induced dissociation mass spectra of the four most
abundant ions in the survey scan. For some analyses,
the survey scan covered a mass range ofm/z 300 to 2000;
for other experiments, a sample was injected twice,
using ranges of m/z 300 to 900, and 900 to 2000 to
maximize the coverage of IRS-1. Additional scan strat-
egies were subsequently utilized for the relative quan-
tification analyses, as described in the Results and
Discussion section. All uninterpreted tandem MS data
were searched using Mascot. Assignments of the phos-
phopeptides were confirmed by manual comparison of
the tandem mass spectra with the predicted fragmenta-
tion generated in silico by GPMAW (Lighthouse Data,
Odense, Denmark) and/or the MS-Product component
of ProteinProspector (http://prospector.ucsf.edu).
Statistical Analyses
Statistical significance was assessed by one-way analy-
sis of variance (ANOVA) followed by pairwise compar-ison assessment by the Student-Newman-Keuls (SNK)
test.
Results and Discussion
Selection of Representative Peptides Derived
from Human IRS-1
Full-length human IRS-1 samples expressed in L6 cells
were prepared in four independent experiments, and at
least two HPLC-ESI-MS/MS analyses of each sample
were performed using a standard “top-4” data-dependent
scan strategy. MALDI-TOF/MS and HPLC-ESI-MS/MS
analysis of the tryptic digests confirmed the presence of
IRS-1 (40% coverage; Sprot database analysis by Mascot).
Based on results from these analyses, six “representative”
IRS-1 peptides (Table 1) that were reproducibly detected
in the tryptic digest were selected according to the follow-
ing criteria: (1) detected by HPLC-ESI-MS with high
intensity among IRS-1 peptides; (2) no missed cleavage
observed; (3) no methionine in the sequence to avoid
variability due to methionine oxidization; (4) distributed
throughout the IRS-1 sequence.
Identification and Relative Quantification
of Phosphopeptides Derived from Human IRS-1
During the course of our analyses of IRS-1 expressed in
L6 cells, several phosphopeptides were identified and
verified by targeted MS/MS. Analogous to our recent
report on phosphorylation in IRS-1 expressed in HEK-
293 cells [10], in the current experiments we again
identified Ser1078 in VNLpSPNR as a site of phosphor-
ylation. The unphosphorylated counterpart of this pep-
tide is one of the six representative IRS-1 peptides used
as endogenous standards in these studies. In addition,
Thr446 in SVpTPDSLGHTPPAR was identified as a
novel phosphorylation site in IRS-1 expressed in L6
cells. Relative changes in the quantities of these two
IRS-1 phosphopeptides were then assessed in response
to stimuli, as described below.
IRS-1 was isolated from L6 cells that were either
untreated or exposed to insulin or TNF as described in
Methods. Each tryptic digest was analyzed in quadru-
Table 1. IRS-1 peptides used to assess relative quantification at
specific phosphorylation sites
Residues Sequence Molecular weighta (Da)
29–33 FFVLR 681.4
178–184 NLIGIYR 848.5
573–580 HSAFVPTR 914.5
639–651 SVSAPQQIINPIR 1422.8
1017–1028 TGIAAEEVSLPR 1242.7
1075–1081 VNLSPNR 799.4
AngI DRVYIHPFHL 1296.7
AngII DRVYIHPF 1046.5
aMonoisotopic valuesplicate by HPLC-ESI-MS/MS using a scan protocol
ding
st.
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scan (with the 2 charge states of the six representative
IRS-1 peptides included in the list), and two targeted
MS/MS scans (for the 2 ions of the phosphopeptides
of interest). Combined peak areas for the 1, 2, and
3 (when detected) charge states for each peptide were
obtained by integration of the appropriate recon-
structed ion chromatograms. Peak areas for AngI and
AngII were also determined. The values obtained for
the six IRS-1 peptides were summed and the average
used for subsequent normalization of phosphopeptide
peak areas. In all analyses, the tandem mass spectra
obtained for each peptide of interest were used to verify
identity. In Table 2 can be seen the average of the
combined charge state peak areas for the six represen-
tative IRS-1 peptides and the phosphopeptides contain-
ing Thr446 and Ser1078 in addition to that for AngII.
(Note that the results obtained when AngI was used as
a reference were essentially the same as for AngII and
are not included in the table.) The relatively low stan-
dard errors for the results in Table 2 demonstrate that
use of the average of the combined peak areas for the
six IRS-1 peptides was an effective way to normalize the
intensity values for the phosphopeptides of interest to
compensate for differences in sample quantity and
injection volume.
As can be seen in Table 2, the normalized peak areas
for the peptide containing Ser1078 in IRS-1 (VNLpSPNR)
Table 2. Relative quantification of phosphopeptides in IRS-1
Sampleb Peak intensitya
AngII Avg. of 6 IRS-1 pep. IRS-11075–1081
Control
C1 2.31E 07 2.25E 07 2.65E 06
C2 1.26E 08 1.08E 08 1.14E 07
C3 2.84E 08 3.10E 08 3.83E 07
C4 1.17E 08 1.36E 08 1.25E 07
Mean s.e.
rel. quant.
Insulin
I1 3.10E 08 2.88E 08 3.36E 07
I2 1.23E 08 1.63E 08 1.90E 07
I3 7.96E 07 1.06E 08 1.28E 07
I4 7.67E 07 8.02E 07 8.80E 06
Mean s.e.
rel. quant.
TNF
T1 8.22E 07 7.35E 07 1.14E 07
T2 1.47E 08 1.45E 08 1.57E 07
T3 1.97E 08 2.13E 08 2.26E 07
T4 1.69E 08 1.79E 08 1.52E 07
Mean s.e.
rel. quant.
aCombined peak areas for the 1, 2, and 3 (when detected) charg
reconstructed ion chromatograms.
bIRS-1 was isolated by immunoprecipitation after expression in L6 cells,
was digested in situ by trypsin and analyzed by HPLC-ESI-MS/MS.
cStatistically significant difference (P  0.05) compared to the correspon
assessment of pairwise comparisons by the Student-Newman-Keuls teisolated from insulin- or TNF-treated L6 cells wereessentially the same as for VNLpSPNR obtained from
untreated L6 cells: (control, 0.110  0.007; insulin-
treated L6 cells, 0.116  0.002; TNF-treated L6 cells,
0.114 0.015), indicating that exposure to either insulin
or TNF did not affect the degree of phosphorylation at
this site. In contrast, the results reveal that for pThr446
(in SVpTPDSLGHTPPAR) there was an 80% increase
in the normalized peak area for IRS-1 peptides isolated
from either insulin- or TNF-treated L6 cells compared
to peptides obtained from untreated cells: (control,
0.076  0.007; insulin-treated L6 cells, 0.137  0.014;
TNF-treated L6 cells, 0.136  0.009). The change in
relative phosphorylation at this site induced by insulin
or TNF was found to be statistically significant by
ANOVA with pairwise comparisons assessed by the
Student-Newman-Keuls (SNK) test. A bar graph illus-
trating the effects of insulin and TNF on phosphory-
lation at Ser1078 and Thr446 in IRS-1 is shown in Figure 1.
It is important to note that when the ratios of the peak
areas for the average of the six IRS-1 peptides were
compared to AngII, the following values were obtained:
control L6 cells, 1.021  0.067; insulin-treated L6 cells,
1.158  0.102; TNF-treated L6 cells, 1.005  0.042.
These results indicate that there were no substantial
changes in the overall level of IRS-1 induced by treat-
ment with either insulin or TNF.
The results presented above demonstrate that HPLC-
ESI-MS peak areas of selected endogenous peptides can
Relative to average
of six IRS-1 peptides
Relative
to AngII
444–457 IRS-11075–1081 IRS-1444–457 IRS-11075–1081 IRS-1444–457
E 06 0.12 0.08 0.11 0.07
E 07 0.11 0.09 0.09 0.08
E 07 0.12 0.06 0.13 0.06
E 07 0.09 0.08 0.11 0.09
0.110 0.007 0.076 0.007 0.112 0.009 0.076 0.007
1.00 1.00 1.00 1.00
E 07 0.12 0.12 0.11 0.11
E 07 0.12 0.12 0.15 0.16
E 07 0.12 0.18 0.16 0.24
E 07 0.11 0.13 0.11 0.14
0.116 0.002 0.137 0.014c 0.135 0.013 0.162 0.028c
1.06 1.82 1.20 2.11
E 06 0.16 0.12 0.14 0.11
E 07 0.11 0.15 0.11 0.15
E 07 0.11 0.15 0.11 0.16
E 07 0.09 0.12 0.09 0.12
0.114 0.015 0.136 0.009c 0.113 0.010 0.137 0.012c
1.04 1.79 1.01 1.79
tes for each peptide were obtained by integration of the appropriate
scribed in Methods. After separation by 1-D SDS PAGE, the IRS-1 band
control group as assessed by a 1-way analysis of variance followed byIRS-1
1.60
1.00
1.79
1.10
3.35
2.00
1.90
1.05
9.00
2.20
3.20
2.11
e sta
as debe successfully used as internal standards to assess
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to cellular stimuli such as insulin and TNF. Thr446 in
SVpTPDSLGHTPPAR is a newly discovered phosphor-
ylation site in IRS-1 expressed in L6 cells. After stimu-
lation with either insulin or TNF, phosphorylation at
Thr446 was found to increase by 80%. Ser1078 (in
VNLpSPNR) is a phosphorylation site we have previ-
ously identified in IRS-1 expressed in HEK-293 cells
[10]. In contrast to Thr446, we saw no changes in the
relative degree of phosphorylation at this site upon
stimulation with insulin or TNF. The unphosphory-
lated form of this peptide was used as one of the six
representative IRS-1 peptides; the abundance of the
unphosphorylated peptide also remained constant in
the untreated and treated samples. It is important to
note that the intensities of the variously-charged ions
representing VNLSPNR were 8 to 10 times higher than
the corresponding ions for VNLpSPNR, thereby mak-
ing it possible to include VNLSPNR among the repre-
sentative IRS-1 peptides used for normalization. In the
event that there might be a high degree of phosphory-
lation at Ser1078, it would be necessary to either pick an
alternative peptide from the C-terminal region of IRS-1
or else only use the other five peptides for normaliza-
tion.
In the method described here, representative pep-
tides derived from the protein of interest were used to
normalize the phosphopeptide intensity data. As such,
it was possible to directly assess relative changes in
phosphorylation at targeted sites. The avoidance of
methionine-containing sequences as well as peptides
exhibiting missed tryptic cleavages helped to enhance
the reproducibility of detection of the representative
Figure 1. Relative quantification of phosphopeptides of IRS-1
expressed in L6 cells. Following treatment with insulin or TNF,
IRS-1 was isolated by immunoprecipitation, as described in Meth-
ods. After separation by 1-D SDS PAGE, each IRS-1 band was
digested in situ with trypsin and analyzed by HPLC-ESI-MS/MS.
Normalization of peak areas for the phosphopeptides using 6
endogenous IRS-1 representative peptides was accomplished as
described in Methods. Values represent the mean  standard
error of the mean for 4 HPLC-ESI-MS/MS analyses of the same
sample; asterisk, statistically significant difference (P  .05) com-
pared to the corresponding control group as assessed by a
one-way analysis of variance followed by pairwise comparisons
using the Student-Newman-Keuls test.peptides. Moreover, selection of peptides distributedthroughout the IRS-1 sequence gave a more global
assessment of the digestion. And, by averaging the
combined charge state peak areas for the six represen-
tative peptides in the control and experimental samples,
it was possible to minimize differences in individual
peptides.
An important aspect of our approach for relative
quantification of phosphopeptides is that tandem mass
spectra were acquired for all endogenous and phos-
phorylated peptides of interest to verify that the MS
intensities being used were associated with the correct
peptide. By using a combination of a parent list for the
relatively intense representative IRS-1 peptides and a
target scan list for the less intense phosphopeptides, we
could be certain that all necessary tandem mass spectra
would be acquired. Moreover, inclusion of AngI and
AngII as reference standards made it possible to verify
the analytical results for the IRS-1 representative pep-
tides and to assess the relative quantity of IRS-1 in
different samples.
A major advantage of the approach described here is
that it does not require derivatization or isotopic label-
ing, thus minimizing sample processing and eliminat-
ing sources for potential experimental variation. In
addition, this method can be applied to a wide variety
of cell lines and tissues since metabolic labeling is not
involved. In numerous reports in the literature, assess-
ment of changes in phosphorylation has been made by
immunoblot analysis. However there are no commer-
cially available phospho-specific antibodies for many of
the identified phosphorylation sites, such as Thr446 or
Ser1078 in IRS-1. Use of the MS based strategy described
here enabled us to evaluate relative changes in phos-
phorylation at these two IRS-1 sites in response to
exposure of L6 cells to insulin or TNF. Experiments
such as these are important for elucidating the func-
tional consequences of phosphorylation at these sites in
vivo and might lead to new insights into insulin resis-
tance and type-2 diabetes. We are planning to apply this
approach to the relative quantification of phosphoryla-
tion of IRS-1 in human muscle obtained from normal
subjects and people with type-2 diabetes.
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